Clinical trialObsCompleted
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
Multicenter Retrospective Analysis for Efficacy and Safety of Second-Line Nab-Paclitaxel Plus Gemcitabine After Progression on 1st-line FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma
- Outcome
- Finished, no results posted
- Phase
- Obs
- Status
- Completed
- Study type
- Observational
- Start
- 16 September 2019
- Expected end
- 1 February 2020
- Enrollment
- 103 participants
- Sites
- 1
- Primary outcomes
- Progression-free survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 13 March 2020
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 4
- Builds on itEfficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or … DOI 10.1177/1758835920923424↗
- BackgroundUse of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocar… DOI 10.3892/ol.2017.6061↗
- BackgroundRole of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospecti… DOI 10.3978/j.issn.2078-6891.2015.041↗
- BackgroundSustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: repor… DOI 10.1016/j.clinre.2014.01.005↗